Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Dearnaley

Showing results (81-90 of 148) with videos related to

Pageof 15
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 30, 2019
Patterns of recurrence after prostate bed radiotherapyDouglas H Brand, Joanna I Parker, David P Dearnaley, et al.
International Journal of Radiation Oncology, Biology, Physics|January 7, 2021
Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP TrialDouglas H Brand, Sarah C Brüningk, Anna Wilkins, et al.
The Lancet. Oncology|January 2, 2013
Stereotactic body radiotherapy for oligometastasesAlison C Tree, Vincent S Khoo, Rosalind A Eeles, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 24, 2004
Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvementElizabeth J Adams, David J Convery, Vivian P Cosgrove, et al.
Journal of the National Cancer Institute|May 17, 2007
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)Malcolm D Mason, Matthew R Sydes, John Glaholm, et al.
Journal of the National Cancer Institute|September 4, 2003
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)David P Dearnaley, Matthew R Sydes, Malcolm D Mason, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 30, 2007
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)David P Dearnaley, Matthew R Sydes, Ruth E Langley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 22, 2007
A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancerTeresa Guerrero Urbano, Catharine H Clark, Vibeke N Hansen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 24, 2017
Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate CancerMiguel Reis Ferreira, Atia Khan, Karen Thomas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 2, 2007
Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I studyTeresa Guerrero Urbano, Catharine H Clark, Vibeke N Hansen, et al.
Pageof 15

Showing results (81-90 of 148) with videos related to

Sort By:
Pageof 15
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 30, 2019
Patterns of recurrence after prostate bed radiotherapyDouglas H Brand, Joanna I Parker, David P Dearnaley, et al.
International Journal of Radiation Oncology, Biology, Physics|January 7, 2021
Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP TrialDouglas H Brand, Sarah C Brüningk, Anna Wilkins, et al.
The Lancet. Oncology|January 2, 2013
Stereotactic body radiotherapy for oligometastasesAlison C Tree, Vincent S Khoo, Rosalind A Eeles, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 24, 2004
Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvementElizabeth J Adams, David J Convery, Vivian P Cosgrove, et al.
Journal of the National Cancer Institute|May 17, 2007
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)Malcolm D Mason, Matthew R Sydes, John Glaholm, et al.
Journal of the National Cancer Institute|September 4, 2003
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)David P Dearnaley, Matthew R Sydes, Malcolm D Mason, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 30, 2007
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)David P Dearnaley, Matthew R Sydes, Ruth E Langley, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 22, 2007
A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancerTeresa Guerrero Urbano, Catharine H Clark, Vibeke N Hansen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 24, 2017
Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate CancerMiguel Reis Ferreira, Atia Khan, Karen Thomas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 2, 2007
Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I studyTeresa Guerrero Urbano, Catharine H Clark, Vibeke N Hansen, et al.
Pageof 15